Growth Equity Opportunities Fund IV, LLC 13D and 13G filings for Addex Therapeutics Ltd:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-04-10 4:06 pm Unchanged | 2023-04-04 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 385,230 8.500% | 0 (Unchanged) | Filing |
| 2022-11-28 3:19 pm Unchanged | 2022-11-22 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 385,230 9.700% | 0 (Unchanged) | Filing |
| 2022-08-23 5:18 pm Unchanged | 2022-07-26 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 385,230 15.100% | 0 (Unchanged) | Filing |
| 2022-01-10 1:15 pm Unchanged | 2021-12-16 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 385,230 20.400% | 0 (Unchanged) | Filing |
| 2021-01-21 6:47 pm Purchase | 2021-01-11 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 385,230 21.500% | 385,230 (New Position) | Filing |